News about Pfizer funding research on how its drug, Axitinib, affects cancer through the National Comprehensive Cancer Network, including adenoid cystic carcinoma:
http://www.businesswire.com/news/home/20110705005836/en/Researchers-Receive-Grants-NCCN-Oncology-Research-Program
Sites that were awarded, and type of cancer studied (links to these centers and names of researchers are in the article above):
-Memorial Sloan-Kettering Cancer Center (ACC)
-Roswell Park Cancer Institute (advanced melanoma)
-H. Lee Moffitt Cancer Center & Research Institute (advanced carcinoid tumors)
-University of Michigan Comprehensive Cancer Center (head/neck cancer)
Other studies on this drug in the Clinical Trials database:
http://clinicaltrials.gov/ct2/results?term=axitinib
Research published that mentions the drug name and/or number:
http://www.ncbi.nlm.nih.gov/pubmed?term=axitinib%20OR%20AG013736
Mention of the drug in financial news:
http://search.cnbc.com/main.do?target=all&keywords=axitinib&categories=exclude
The search function on the FDA drug site didn't retrieve anything-but Pfizer has gone for approval, based on its performance on renal cancer:
http://www.fda.gov/Drugs/default.htm
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment